BioSpace News Archive

Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing that a poster has been presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, announced that it has granted equity awards to six employees, none of whom are executive officers, as an inducement for them to accept employment with Surgalign, and representing the right to purchase or receive, in the aggregate, up to 179,667 shares of Surgalign common stock.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced clinical data for lifileucel in combination with pembrolizumab in patients with advanced melanoma.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), today announced the presentation of interim clinical data from its Phase 1b combination therapy study of SBP-101, a proprietary polyamine analogue, with gemcitabine and nab-paclitaxel (G+A) in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDA), at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented data demonstrating the differentiation of balstilimab as an anti-PD-1 antibody as well as data from a Phase 1 clinical trial of AGEN2373.

Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta® (capmatinib) in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14)1-

Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001)

- Updated Data From ARTISTRY Clinical Program Highlight Anti-Tumor Activity as Monotherapy and in Combination With Pembrolizumab - - Data Support Advancement of Regulatory Strategy in Cancers With High Unmet Need - - Company to Host Investor Webcast Today at 4:00 p.m. ET -

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the Phase II SUMMIT basket trial, assessing the efficacy of neratinib in patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the Phase II CONTROL trial with the neratinib treatment arm of the ExteNET Trial